Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
HYAL4 V1
Cancer:
Bladder Cancer
Drug:
gemcitabine
(
DNA synthesis inhibitor
)
Direction:
Resistant
Evidence:
Evidence Level:
Resistant: D – Preclinical
Source:
Clin Cancer Res
Title:
HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer
Published date:
05/24/2021
Excerpt:
V1-expressing bladder cells were resistant to Gemcitabine but not to Cisplatin.
DOI:
10.1158/1078-0432.CCR-21-0422
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.